Literature DB >> 24372790

Not only in trauma patients: hospital-wide implementation of a massive transfusion protocol.

L M Baumann Kreuziger1, C T Morton, A T Subramanian, C P Anderson, D J Dries.   

Abstract

OBJECTIVES: To review outcomes of massive transfusion protocol (MTP) activation and determine the impact of MTP implementation on blood bank use.
BACKGROUND: MTP has been established to rapidly provide plasma and packed red blood cells in ratios approaching 1 : 1. Due to availability, MTP has been utilised in non-traumatic haemorrhage despite evidence of benefit in this population. Our hospital-wide implementation of MTP was reviewed for propriety, outcomes and effect on blood bank resources.
METHODS: Retrospective cohort study of patients receiving transfusion after MTP activation from October 2009 to 2011. Underlying medical conditions and baseline medication use were determined. In-hospital and 24-h mortality were compared with evaluation for confounding by Acute Physiology And Chronic Health Evaluation (APACHE) score and duration of MTP activation. Blood product use before and after MTP implementation was reviewed.
RESULTS: MTP activation occurred in 62 trauma and 63 non-trauma patients. Non-trauma patients were older, had more underlying medical conditions and higher APACHE scores compared with trauma patients; 24-h mortality was higher in trauma compared with non-trauma patients (27·4 vs 11·1%, P = 0·02). There was no significant difference of in-hospital mortality. Transfusion ratio did not differ between trauma and non-trauma patients and was not associated with mortality even when MTP activation duration and APACHE score were considered. Hospital-wide blood product use did not change with MTP implementation.
CONCLUSIONS: MTP may be successfully used in trauma and non-trauma settings without significantly impacting overall blood product utilisation. Inclusion of non-trauma patients into prospective studies of resuscitation with blood products is warranted to ensure benefit in these patients.
© 2013 The Authors. Transfusion Medicine © 2013 British Blood Transfusion Society.

Entities:  

Keywords:  massive transfusion; non-trauma; survival; trauma

Mesh:

Year:  2013        PMID: 24372790      PMCID: PMC4043857          DOI: 10.1111/tme.12096

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  21 in total

1.  The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.

Authors:  Bryan C Morse; Christopher J Dente; Erica I Hodgman; Beth H Shaz; Jeffrey M Nicholas; Amy D Wyrzykowski; Jeffrey P Salomone; Gary A Vercruysse; Grace S Rozycki; David V Feliciano
Journal:  Am Surg       Date:  2011-08       Impact factor: 0.688

Review 2.  Massive transfusion: an evidence-based review of recent developments.

Authors:  Matthew D Neal; Alyce Marsh; Ryan Marino; Benjamin Kautza; Jay S Raval; Raquel M Forsythe; Gary T Marshall; Jason L Sperry
Journal:  Arch Surg       Date:  2012-06

3.  Outcomes after massive transfusion in nontrauma patients in the era of damage control resuscitation.

Authors:  Bryan C Morse; Christopher J Dente; Erica I Hodgman; Beth H Shaz; Anne Winkler; Jeffrey M Nicholas; Amy D Wyrzykowski; Grace S Rozycki; David V Feliciano
Journal:  Am Surg       Date:  2012-06       Impact factor: 0.688

4.  Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.

Authors:  Kwok M Ho; Edward Litton
Journal:  Transfusion       Date:  2011-12-30       Impact factor: 3.157

5.  Transfusion practice in major obstetric haemorrhage: lessons from trauma.

Authors:  I Saule; N Hawkins
Journal:  Int J Obstet Anesth       Date:  2011-11-26       Impact factor: 2.603

Review 6.  Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.

Authors:  Ewurabena Simpson; Yulia Lin; Simon Stanworth; Janet Birchall; Carolyn Doree; Chris Hyde
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

7.  Experience with a massive transfusion protocol in the management of massive haemorrhage.

Authors:  R Sinha; D Roxby; A Bersten
Journal:  Transfus Med       Date:  2013-04       Impact factor: 2.019

8.  The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks.

Authors:  John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

9.  Use of a massive transfusion protocol in nontrauma patients: activate away.

Authors:  Lauren M McDaniel; Matthew D Neal; Jason L Sperry; Louis H Alarcon; Raquel M Forsythe; Darrell Triulzi; Andrew B Peitzman; Jay S Raval
Journal:  J Am Coll Surg       Date:  2013-04-06       Impact factor: 6.113

Review 10.  The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework.

Authors:  Y Lin; C J Moltzan; D R Anderson
Journal:  Transfus Med       Date:  2012-05-27       Impact factor: 2.019

View more
  2 in total

1.  Association Between Ratio of Fresh Frozen Plasma to Red Blood Cells During Massive Transfusion and Survival Among Patients Without Traumatic Injury.

Authors:  Tomaz Mesar; Andreas Larentzakis; Walter Dzik; Yuchiao Chang; George Velmahos; Daniel Dante Yeh
Journal:  JAMA Surg       Date:  2017-06-01       Impact factor: 14.766

2.  Effects of a hospital-wide introduction of a massive transfusion protocol on blood product ratio and blood product waste.

Authors:  Kirsten Balvers; Michiel Coppens; Susan van Dieren; Ingeborg H M van Rooyen-Schreurs; Henriëtte J Klinkspoor; Sacha S Zeerleder; Holger M Baumann; J Carel Goslings; Nicole P Juffermans
Journal:  J Emerg Trauma Shock       Date:  2015 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.